The French pharmaceutical market is forecast to grow at a tepid Compound Annual Growth Rate (CAGR) of 0.7% from $46.2 billion in 2014 to $48.2 billion by 2020, restricted by an increasing focus on generic drugs.
Reportstack’s latest report "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape-France" states that France was a relatively late entrant to the generics market compared to the UK and Germany. In 2008, generic drugs accounted for 21.7% of the pharmaceutical market in terms of volume, which increased to 30.2% in 2013.
The French government is promoting generics as a measure to reduce healthcare expenditure. In September 2012, it introduced a scheme under which patients who agree to generic substitution will not be required to pay for their drugs.
Owide explains: “While patented drugs dominate France’s pharmaceutical market, the volume of prescribing attributed to generic drugs will shift closer to levels seen in the rest of Europe, restricting French market growth.
“The generic sector is mainly driven by a favorable regulatory regime, patent expirations and a variety of government incentives for physicians, pharmacists and patients to choose generics ahead of branded products.”
Despite the negative impact of generics, France’s pharmaceutical market will be boosted by a number of factors, including an aging population, tax incentives, a substantial skilled workforce and high public healthcare expenditure.
“By 2020, France’s elderly population is expected to account for almost 20% of the total population. As this demographic demands more medication than younger demographics, the need for high-quality healthcare is increasing.
“Additionally, numerous incentives, such as the abolition of corporate tax and the Research Tax Credit to support research and development, are enhancing the competitiveness of healthcare enterprises and will help to sustain the pharmaceutical market.”
To access full report with TOC, please visit CountryFocus: Healthcare, Regulatory and Reimbursement Landscape-France.